Richard E. Chipkin

RICHARD E. CHIPKIN is President and Chief Executive Officer of
Psychiatric Genomics, Inc. Dr. Chipkin spent more than 20 years working
in both clinical research and business development at Schering-Plough
Corporation prior to joining Psychiatric Genomics, Inc., in July 2001.
At Schering-Plough, he most recently served in the Global Business
Development Group, where he was responsible for global product licensing
and acquisition in multiple therapeutic areas. In this capacity, Dr.
Chipkin negotiated several multi-million dollar research and development
and development/marketing deals. In addition, he was responsible for
maintaining all business relationships with Japanese pharmaceutical
companies. Earlier in his career at Schering-Plough, he held positions
in both preclinical and clinical neuropharmacology research. Among his
accomplishments in the research arena was the discovery of novel
analgesic and antipsychotic drugs, including the discovery and human
testing of the world’s first selective D1/D5 antagonist. Dr. Chipkin
received his undergraduate degree from the State University of New York
at Albany and his PhD in Pharmacology from the Medical College of
Virginia. He did post-doctoral work at the University of Colorado
Medical Center.